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Abstract IncobotulinumtoxinA (Xeomin, NT 201), a
preparation without accessory (complexing) proteins, has
shown comparable efficacy and safety to onabotulinum-
toxinA in treating cervical dystonia (CD). This study
evaluated the efficacy and safety of repeated incobotuli-
numtoxinA injections in subjects with CD. Following a
B20-week placebo-controlled, randomized, double-blind,
single-dose main period, subjects could enter a B68-week
prospective, randomized, double-blind, repeated-dose,
flexible-interval (minimum 6 weeks) extension period with
240 U or 120 U of incobotulinumtoxinA (B5 injections).
Outcome measures included the Toronto Western Spas-
modic Torticollis Rating Scale (TWSTRS) and adverse
events (AEs). Of 219 subjects completing the main period,
214 were randomized in the extension period to receive
incobotulinumtoxinA 240 U (n = 111) or 120 U
(n = 103); 169 subjects completed the extension period,
with 90 receiving five injection sessions. Both doses of
incobotulinumtoxinA provided statistically significant and
clinically relevant improvements in mean TWSTRS-Total,
-Severity, -Disability, and -Pain scores, from each injection
session to respective 4-week follow-up visits. The most
frequently reported AE was dysphagia (240 U: 23.4 %;
120 U: 12.6 %), which did not result in any study with-
drawals. There was no impact of injection interval on the
incidence of AEs (post hoc analysis). A major limitation of
this study was the fixed dose design requested by regula-
tory authorities, which does not reflect clinical practice.
However, repeated incobotulinumtoxinA injections (240 or
120 U; flexible intervals) provided sustained efficacy and
were well tolerated, with no unexpected safety risks fol-
lowing repeated injections. The incidence of AEs was
similar in subjects requiring repeated injections at shorter
intervals (B12 weeks) compared with those treated using
longer intervals ([12 weeks).
Keywords: Dystonia  Xeomin  IncobotulinumtoxinA 
NT 201  Botulinum toxin
Introduction
Cervical dystonia (CD) is a focal dystonia characterized by
involuntary activation of the muscles of the neck and
shoulders, resulting in abnormal repetitive and/or sustained
posturing. Pain is a recognized clinical feature of CD: over
two-thirds of subjects have associated neck pain (Chan
et al. 1991). The efficacy and tolerability of botulinum
toxin for the treatment of CD are supported by Class I
evidence (Simpson et al. 2008).
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When isolated from Clostridium botulinum cultures,
botulinum toxin is composed of a 150-kDa core neurotoxin
and accessory (complexing) proteins, including hemag-
glutinin and non-toxin non-hemagglutinin (NTNH) pro-
teins (Inoue et al. 1996). IncobotulinumtoxinA (Xeomin;
also known as NT 201; Merz Pharmaceuticals GmbH,
Frankfurt, Germany) is a purified form of botulinum toxin
type A that contains no accessory proteins and has a high
specific biological activity (Frevert 2009, 2010; Frevert and
Dressler, 2010, Dressler 2012). IncobotulinumtoxinA has
shown comparable efficacy and safety to onabotulinum-
toxinA in the treatment of CD when used in a 1:1 dosing
ratio (Benecke et al. 2005) and was equipotent to onabo-
tulinumtoxinA in a mouse toxicity (LD50) assay (Dressler
et al. 2011).
In the double-blind, randomized, placebo-controlled
main period (MP) of a phase 3 study, incobotulinumtoxinA
(240 or 120 U) significantly improved Toronto Western
Spasmodic Torticollis Rating Scale (TWSTRS)-Total
scores and subscores compared with placebo in subjects
with primary CD of a predominantly rotational form
(Comella et al. 2011). While this demonstrates the efficacy
of a single set of incobotulinumtoxinA injections, the
majority of subjects with focal dystonia require long-term
treatment. Herein, we report data from the double-blind
extension period (EP) of this study, which investigated
the safety and efficacy of repeated injection sessions of
incobotulinumtoxinA (240 or 120 U) in subjects with CD
over a 68-week period (including a 20-week safety period).
This is the first randomized trial in CD where the design of
the EP included flexible injection intervals (minimum
6 weeks) to allow tailoring of treatment to meet individual
subject needs.
Methods
The design and results of the placebo-controlled MP of this
double-blind, randomized, parallel-group phase three trial
(clinicaltrials.gov identification number: NCT00407030;
MRZ 60201–0408) have been reported (Comella et al.
2011). The EP had a randomized, double-blind, parallel-
group design and was conducted at 37 centers across the
USA. The total duration of this incobotulinumtoxinA long-
term study (MP plus EP) was up to 88 weeks. The
respective Institutional Review Boards approved the study
protocol and the informed consent process. The study was
conducted in accordance with the ethical principles out-
lined in the declaration of Helsinki and was consistent with
good clinical practice and the applicable regulatory
requirements. Both the MP and EP were monitored by an
independent Data Safety Monitoring Board (DSMB).
Subjects
In the MP, pre-treated and treatment-naı¨ve subjects were
eligible for enrollment (Comella et al. 2011).
Subjects could enter the EP if they had completed the
last visit of the MP and had a need for re-injection, which
the investigator agreed was necessary, as defined by a
TWSTRS-Total score C20 points.
Randomization
Before enrollment into the MP, subjects were randomized
to receive incobotulinumtoxinA (240 or 120 U) or placebo
in the MP. At this time point, independently from ran-
domization to MP treatment, subjects were also random-
ized to receive incobotulinumtoxinA injections at total
doses of either 240 or 120 U in the EP. Randomization was
performed using RANCODE version 3.6 (IDV, Gauting,
Germany). Block-wise randomization (block size of six)
ensured a balanced treatment assignment for each center.
Subjects, investigators, medical staff, and all staff at the
sponsoring company and clinical research organization
were blinded to treatment.
Treatment and follow-up visits
In the EP, subjects received incobotulinumtoxinA at total
doses of 240 or 120 U in an equal total volume of 4.8 mL.
Muscles treated, number of injection sites per muscle, use
of electromyographic guidance, and doses injected at each
site were at the discretion of the investigator. All subjects
could receive one to five injection sessions of incobotuli-
numtoxinA as clinically required over the 48 weeks. The
interval between injection sessions was flexible, with a
minimum interval of 6 weeks up to the time when subjects
expressed a need for a re-injection. To be re-injected,
subjects had to spontaneously request re-treatment and
have a TWSTRS-Total score of C20.
A mandatory telephone call was made on Day 7 ± 1
and a follow-up visit took place on Day 28 ± 3 after each
injection session. The Trial Termination Visit (TTV) was
performed 20 weeks (± 3 days) after the last injection
session or when the subject expressed a need for a new
injection of botulinum toxin other than study medication,
whichever came first (Fig. 1).
Efficacy assessments
The primary and secondary efficacy variables for the MP
have been reported previously (Comella et al. 2011). In the
EP, the following efficacy variables were assessed:
TWSTRS-Total and subscale scores (Disability, Severity,
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and Pain) (Consky and Lang 1994), Investigator Global
Assessment of Efficacy (IGAE), and Patient Evaluation of
Global Response (PEGR) (adapted from Wissel et al.
(2000). TWSTRS-Total and subscale scores were assessed
at each injection session, each follow-up visit, and the
TTV; analyses included changes from each injection ses-
sion to the follow-up visits, and changes from the first
injection session in the EP to the TTV. Assessments were
only performed by investigators who had been appropri-
ately trained, and the same investigator performed all
assessments for a given subject. The IGAE consists of a
4-point Likert scale ranging from 1 (very good) to 4 (poor),
and the PEGR scale ranges from –4 (very marked wors-
ening) to ?4 (complete abolishment of all signs and
symptoms). IGAE and PEGR were recorded at all injection
visits of the EP (except the first) and the TTV, for the
assessment of the respective previous injection cycle.
Safety assessments
Subjects were requested to report all adverse events (AEs)
to the investigator. At each visit and telephone contact,
AEs were evaluated and subjects were specifically asked to
report any swallowing difficulties using a 5-point dyspha-
gia rating scale as 0 (absent, no swallowing difficulties), 1
(mild swallowing difficulties), 2 [moderate, when swal-
lowing solid meals (e.g. meat)], 3 (severe, with swallowing
difficulties and requiring a change in diet), or 4 (swal-
lowing not possible, resulting in weight loss) (Comella
et al. 1992). Any increase in the dysphagia scale score after
an injection session was classified as an AE.
Vital signs, including systolic/diastolic blood pressure,
respiratory rate, and heart rate, were assessed at each visit.
Physical and neurological examinations were performed at
the third injection visit of the EP and the TTV. Blood
samples for clinical chemistry and hematology, and for the
determination of antibodies against botulinum toxin type
A, were taken at all visits for evaluation at a central lab-
oratory. Antibodies against botulinum neurotoxin type A
were assessed by a validated fluorescence immunoassay for
antibodies (FIA-AB). To identify neutralizing antibodies,
samples that were positive in the FIA-AB were tested with
a mouse ex vivo hemidiaphragm assay (HDA) (Go¨schel
et al.1997; Sesardic et al. 2004). FIA-ABs were performed
by BioProof AG, Munich, Germany, and HDAs were
performed by Toxogen GmbH, Hannover, Germany. For
the assessment of the respective previous injection cycle,
the Investigator Global Assessment of Tolerability (IGAT)
scale, a 4-point Likert scale ranging from 1 (very good) to
4 (poor) was performed at all injection visits of the EP
(except the first) and the TTV.
Statistical methodology
Efficacy results represent the intent-to-treat population, and
safety data represent the evaluable-for-safety population
(both defined as all subjects who received any amount of
study medication during the MP or EP). Study completers
(as defined at a blind data review meeting during the EP
and prior to data availability) were required to have met
one of the following criteria: subjects who completed the
trial according to the investigator; subjects who did not
have a TTV, but participated in the EP for C48 weeks;
subjects who received onabotulinumtoxinA but partici-
pated in the EP for at least 48 weeks prior to onabotuli-
numtoxinA injection; or subjects who received the
maximum of five injection sessions, even though the
minimum EP duration of 48 weeks was not fulfilled.
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Fig. 1 Study design. The maximum duration of the extension period
for each individual subject was 68 weeks. aIndividual duration of
placebo-controlled period per subject. bTelephone contact 1 week
after injection session, follow-up visits 4 and 8 weeks after injection
session. cTelephone contacts 1 week after each injection session,
follow-up visits 4 weeks after each injection session
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Statistical analyses were performed with the SASTM
System (Cary, NC, USA), version 8.2 or later. TWSTRS
scores were analyzed using exploratory t-tests.
AEs were encoded using the medical dictionary for
regulatory activities, version 9.1. In a post hoc analysis, a
Chi-square test was used to compare the overall occurrence
of AEs between groups of subjects with different median
injection intervals (6 to B10 weeks, [10 to B12 weeks,
[12 to B14 weeks, or [14 weeks).
Results
Subjects
Of the 219 subjects who completed the MP, 217 enrolled in
the EP. Of those enrolled, three subjects showed no need for
re-injection at 20 weeks after the MP injection session, while
214 subjects who received either incobotulinumtoxinA (240
or 120 U) or placebo in the MP were randomized to receive
incobotulinumtoxinA 240 U (n = 111) or 120 U (n = 103;
Fig. 2). In total, 169 subjects (79.0 %) completed the EP
[240 U, n = 90 (81 %); 120 U, n = 79 (77 %)] (Fig. 2),
with 90 subjects receiving the maximum of five injection
sessions (240 U, n = 53; 120 U, n = 37). The first subject
entered the EP on October 5, 2006, and the last subject
completed the study on June 19, 2009.
Demographic characteristics and TWSTRS-Total scores
and subscores were well balanced between the dose groups
at EP baseline (Table 1). Prior to the MP, 132 had been
previously treated with botulinum toxin, and 82 had been
treatment-naı¨ve. Swallowing difficulties, as recorded using
the dysphagia scale, were reported by 14.6 % of subjects
prior to the MP baseline. Demographic data for pre-treated
and treatment-naı¨ve subjects were comparable with the
total population data of the respective dose groups.
Treatment efficacy
Both doses of incobotulinumtoxinA significantly improved
mean TWSTRS-Total score at 4 weeks after each injection
session throughout the EP (p \ 0.001 vs injection visit;
Fig. 3a, b). There were also significant mean improvements
[standard deviation (SD)] in TWSTRS-Total scores
between the first injection session of the EP and the TTV,
in both dose groups [240 U (n = 81), –4.5 (7.82); 120 U
(n = 66), -6.7 (9.20); p \ 0.001 for both groups]. Mean
TWSTRS-Severity, TWSTRS-Disability, and TWSTRS-
Pain subscales followed a pattern similar to the respective
mean TWSTRS-Total scores (Fig. 3c, d). There were sig-
nificant mean changes from all injection sessions to their
respective 4-week follow-up visits in the 240 and 120 U
groups for all subscale scores (p B 0.016). Treatment dif-
ferences (mean changes in TWSTRS-Total score and mean
changes in TWSTRS subscale scores) between the 240 and
120 U groups were statistically not significant.
Treatment efficacy was assessed by the investigator as
‘‘very good’’ or ‘‘good’’ in the majority of subjects for
injection cycles 1–4 and at the TTV [240 U: 75/100
(75.0 %), 77/89 (86.5 %), 64/80 (80.0 %), 43/53 (81.1 %),
Randomization during main
period:
     Placebo group n = 31
     120 U group n = 31
     240 U group n = 41
Willing to continue into
extension period
n = 217 Never injected with
incobotulinumtoxinA after






















Insufficient efficacy n = 11
Occurrence of withdrawal criteria n = 3
Withdrawal of consent n = 2
Lost to follow-up n = 2
Adverse event n = 1
Other n = 2
Randomization during main
period:
     Placebo group n = 37
     120 U group n = 42
     240 U group n = 32
Insufficient efficacy n = 10
Occurrence of withdrawal criteria n = 4
Withdrawal of consent n = 4
Lost to follow-up n = 3
Other n = 3
Fig. 2 Subject flow diagram
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73/101 (72.3 %); 120 U: 64/91 (70.3 %), 59/79 (74.7 %),
43/59 (72.9 %), 27/37 (73.0 %), 71/91 (76.3 %), respec-
tively]. Mean scores remained similar throughout the EP
(240 U, 1.7–2.0 points; 120 U, 1.8–2.0 points).
At least a moderate improvement (C2 points) in Patient
Evaluation of Global Response (PEGR) was reported by
the majority of subjects for injection cycles 1–4 and at the
TTV [240 U: 70/100 (70.0 %), 70/89 (78.7 %), 60/80
(75.0 %), 35/53 (66.0 %), 63/101 (62.4 %); 120 U: 59/91
(64.8 %), 51/79 (64.6 %), 36/59 (61.0 %), 23/37 (62.2 %),
58/90 (64.4 %), respectively].
Investigator global assessment of tolerability (IGAT)
IGAT ratings were ‘‘very good’’ or ‘‘good’’ for the majority
of subjects for injection cycles 1–4 and at the TTV [240 U
group: 94/100 (94.0 %), 88/89 (98.9 %), 77/80 (96.3 %),
52/53 (98.1 %), 94/102 (92.2 %); 120 U group: 87/91
(95.6 %), 77/79 (97.5 %), 54/59 (91.5 %), 37/37
(100.0 %), 87/93 (93.5 %), respectively].
Adverse events
During the 68-week EP (B5 injection sessions), the inci-
dence of AEs per injection interval was 38.8–61.3 % in the
240 U group and 29.7–47.6 % in the 120 U group, while
the incidence of adverse drug reactions (ADRs) was
5.4–20.4 % in the 240 U group and 10.0–28.8 % in the
120 U group. The overall incidences of ADRs for all
injection intervals are shown in Table 2. Dysphagia,
assessed using a 5-point dysphagia scale, was the most
frequently reported ADR, with a greater incidence per
injection interval in the 240 U group (ranging from 3.8 to
13.5 %) than the 120 U group (ranging from 1.3 to 5.8 %).
No subjects withdrew from the study due to dysphagia.
Most ADRs were of mild (n = 58, 27.1 %) or moderate
(n = 38, 17.8 %) intensity. Severe ADRs were reported by
seven subjects (6.3 %) in the 240 U group and eight
(7.8 %) in the 120 U group. The most common severe
ADRs were neck pain (n = 5, 2.3 %), musculoskeletal
pain (n = 4, 1.9 %), dysphagia, and headache (n = 3,
1.4 % for each). ADRs were not recovered/resolved in nine
subjects (4.2 %) at the end of the study [dysphagia was the
ADR most frequently reported as not recovered/resolved
(n = 3)]. The highest incidence of ADRs occurred after the
first injection session of the EP, both in pre-treated
(n = 23, 17.4 %) and treatment-naı¨ve subjects (n = 30,
36.6 %). There was no cumulative effect of repeated
injection sessions on the incidence of ADRs over the
treatment period. Serious AEs were experienced by 11
subjects; none were considered to be related to study
treatment.
Of 783 re-injections in the EP, 674 (86.1 %) were
administered after an interval of C6 to B20 weeks; the
mean (SD) injection interval was 14.0 (7.4) weeks and the
median injection interval was 13.0 weeks. Of 191 subjects
who received C2 injection sessions, the median injection
interval was 6 to B10 weeks in 43 (22.5 %) subjects, [10
to B12 weeks in 47 (24.6 %) subjects, [12 to B14 weeks
in 37 (19.4 %) subjects, and [14 weeks in 64 (33.5 %)
subjects. In a post hoc analysis, there were no significant
differences in the overall occurrence of AEs between these
groups (p = 0.1117).
There were no clinically significant changes in hema-
tology or clinical chemistry from the first injection session
to the TTV. No pathological tendencies or deteriorations in
neurological status were observed; most subjects had nor-
mal findings for all categories of the physical and neuro-
logical examinations at both the third injection session and
the TTV.
Neutralizing antibodies
Six subjects, who had all received botulinum toxin prior to
the study, tested positive for neutralizing antibodies at
screening for the main phase of the study and at the end of
the extension phase of the study as assessed using the HDA
(subsequent to a positive FIA).





Male, n (%) 42 (37.8) 34 (33.0)
Mean age, years (SD) 52.4 (12.0) 53.6 (11.2)
Mean BMI, kg/m2 (SD) 26.6 (4.9) 27.6 (5.5)
Race, n (%)
American Indian or Alaskan Native 0 1 (1.0)
Asian 1 (0.9) 2 (1.9)
Black or African American 3 (2.7) 1 (1.0)
Hispanic or Latino 4 (3.6) 6 (5.8)
White 103 (92.8) 93 (90.3)
Treatment in MP, n (%)
IncobotulinumtoxinA 240 U 32 (28.8) 41 (39.8)
IncobotulinumtoxinA 120 U 42 (37.8) 31 (30.1)
Placebo 37 (33.3) 31 (30.1)
Mean TWSTRS-Total score (SD) 40.2 (9.6) 41.1 (10.6)
Mean TWSTRS-Severity score (SD) 17.5 (4.4) 17.8 (4.5)
Mean TWSTRS-Disability score (SD) 12.1 (4.4) 12.2 (5.1)
Mean TWSTRS-Pain score (SD) 10.5 (4.1) 11.1 (4.1)
BMI body mass index, MP main period, SD standard deviation,
TWSTRS Toronto Western Spasmodic Torticollis Rating Scale
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Discussion
This randomized, double-blind, repeated-dose, flexible-
interval extension study, with a duration of up to 88 weeks
(MP plus EP), shows that repeated injections of incobo-
tulinumtoxinA, at total doses of 240 or 120 U, are effica-
cious and well tolerated in the treatment of CD.
Improvements in mean TWSTRS scores were considered
clinically relevant and comparable with results of pub-
lished studies (Benecke et al. 2005; Brin et al. 2008;
Comella et al. 2005, 2011; Truong et al. 2005).
IncobotulinumtoxinA was well tolerated with no unex-
pected safety risks following repeated injections. Dyspha-
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Fig. 3 TWSTRS-Total and subscores at each injection session of the
EP and the respective follow-up visits 4 weeks later (ITT population).
Mean TWSTRS-Total scores in 240 U dose group (a); mean
TWSTRS-Total scores in 120 U dose group (b); mean changes in
TWSTRS-Total scores and subscores in 240 U dose group (c); mean
changes in TWSTRS-Total scores and subscores in 120 U dose group
(d) *p \ 0.05; **p \ 0.01; ***p \ 0.001. Error bars represent
standard deviation Numbers of subjects as shown in Fig. 3a and b,
with the following exceptions: Injection session 1, 120 U: TWSTRS-
Severity and -Disability subscales, n = 101 Injection session 3,
240 U: TWSTRS-Pain subscale, n = 86 Injection session 3, 120 U:
TWSTRS-Severity, -Disability, and -Pain subscales, n = 73 EP
extension period, ITT intent-to-treat, Pre at each injection session,
Post at a follow-up visit 4 weeks after the respective injection session,
TWSTRS Toronto Western Spasmodic Torticollis Rating Scale
Table 2 ADRs affecting C5 % of subjects over all injection inter-
vals (evaluable-for-safety population)




Any ADR 48 (43.2) 38 (36.9)
Dysphagiaa 26 (23.4) 11 (10.7)
Injection-site pain 13 (11.7) 7 (6.8)
Muscular weakness 7 (6.3) 8 (7.8)
Neck pain 8 (7.2) 7 (6.8)
Musculoskeletal pain 6 (5.4) 5 (4.9)
ADR adverse drug reaction
a Subjects were specifically asked to report any swallowing diffi-
culties using a 5-point dysphagia scale (Comella et al. 1992); increase
in score after an injection session was considered as an adverse event
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injection interval comparable to rates described for other
botulinum toxin preparations used to treat CD (Allergan,
Inc 2011; Ipsen Biopharm Ltd 2009). Of note, in this study,
unlike in previous studies of other botulinum toxins for
CD, direct questioning using a 5-point dysphagia scale may
have prompted a greater level of reporting by subjects.
Incidences of ADRs did not increase with repeated injec-
tions, suggesting that there were no cumulative effects.
This is the first randomized trial in which flexible
injection intervals were used in registration trials in the
evaluation of repeated treatment of CD with botulinum
toxin. Current US prescribing information for formulations
of botulinum toxin type A suggests a minimum interval of
12 weeks between injection sessions, primarily due to
concerns regarding safety and formation of neutralizing
antibodies (Greene et al. 1994; Allergan Inc 2011; Merz
Pharmaceuticals GmbH 2011; Ipsen Biopharm Ltd 2009).
However, in this study of incobotulinumtoxinA, flexible
injection intervals (minimum 6 weeks) were utilized at the
discretion of the investigator depending on individual
subject needs. This approach enabled individualized treat-
ment for subjects who may derive greater benefit from
more flexible dosing. In this study, 47.1 % of subjects with
[2 incobotulinumtoxinA injections had a median injection
interval B12 weeks and 22.5 % had a median injection
interval B10 weeks. This is in line with the results of a
multi-national survey of botulinum toxin injectors and
subjects who were receiving onabotulinumtoxinA or
abobotulinumtoxinA for the treatment of CD, which
showed that [46 % of subjects would prefer shorter
injection intervals (B10 weeks) compared with those
intervals actually received (Sethi et al. 2012). However, it
has to be emphasized that the mean (SD) injection interval
in this EP was 14.0 (7.4) weeks (median injection interval:
13.0 weeks). Importantly, the current study did not show
significant differences in the incidence of AEs between
subjects who received injection sessions at a median
interval of 6 to B10 weeks and those treated less fre-
quently, indicating that there are no additional safety
concerns associated with shorter injection intervals when
incobotulinumtoxinA is injected repeatedly according to
subject needs with a flexible dosing period of up to 68 and
a total duration of up to 88 weeks (up to six injections). For
the 88-week duration of this study, there was no difference
in the number of subjects testing positive for neutralizing
antibodies in the HDA assay at the beginning of the main
phase of the study versus the end of the EP. However, as
the development of antibodies can occur with a longer
treatment duration (Dressler 2002; Naumann et al. 2010)
further studies with a larger number of subjects over a
longer period are required to further evaluate the immu-
nogenicity of repeated botulinum toxin treatments admin-
istered with flexible dosing intervals.
Neither the MP nor the EP was designed or powered to
identify differences between the two dose groups and,
accordingly, statistical analyses of treatment differences
between the dose groups did not reach significance. To meet
the requirements specified by regulatory authorities, sub-
jects in this trial received randomized, fixed doses of inc-
obotulinumtoxinA. Thus, total doses were not based on
individual subjects’ medical needs and condition and did not
take into consideration any previous botulinum toxin treat-
ment outcomes subjects may have experienced, as would be
standard practice in the treatment of CD outside a clinical
trial setting. Re-randomization at the beginning of the EP
also led to approximately two-thirds of subjects switching
dose groups between the MP and the EP. As a result, sub-
jects may have been over- or under-dosed, which may
potentially have impacted on the frequency of AEs and/or
withdrawals. Thus, it is inappropriate to draw definitive
conclusions regarding differences between dose groups and
purposely designed dose titration studies will be required to
evaluate dosing for botulinum toxin treatment of CD.
Nonetheless, similar to the results from the MP of this study,
both doses of incobotulinumtoxinA demonstrated efficacy.
In summary, this randomized, double-blind extension
study shows that repeated injections of incobotulinumtoxinA
provide sustained efficacy for up to five treatment cycles
when administered at total doses of 240 or 120 U using
flexible dosing intervals according to subject need. Fur-
thermore, incobotulinumtoxinA was well tolerated, and no
unexpected safety risks emerged following repeated injec-
tions. No additional safety concerns were observed in sub-
jects who received injection sessions at short intervals (6 to
B10 or [10 to B12 weeks) compared with those who
received injection sessions at longer intervals ([12 weeks).
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